5th Circ. Affirms Brand, Generic Wins In Reglan Suits

Law360, New York (February 21, 2014, 7:02 PM EST) -- The Fifth Circuit on Friday upheld victories for brand-name and generic makers of the heartburn drug Reglan in two personal injury lawsuits, rejecting the plaintiffs' assertion that their claims against the generic makers are not preempted because they parallel federal law.

In a nonprecedential opinion, the appeals court affirmed the dismissal of claims against generic manufacturers Watson Pharma Inc., Watson Laboratories Inc., Teva Pharmaceuticals USA Inc., Pliva Inc. and Vintage Pharmaceuticals LLC and the granting of summary judgment in favor of Pfizer Inc., Wyeth Inc. and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Walter Lashley v. Pfizer, Incorporated, et al


Case Number

12-60861

Court

Appellate - 5th Circuit

Nature of Suit

4365 P.I. - Product Liability

Date Filed

November 4, 2012


Case Title

Maria Del Valle v. Pliva, Inc., et al


Case Number

12-41148

Court

Appellate - 5th Circuit

Nature of Suit

4365 P.I. - Product Liability

Date Filed

October 15, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.